# Myosin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myosin-therapeutics

- Industry: Biotechnology
- Headquarters: Jupiter, US
- Website: www.myosintherapeutics.com
- Total disclosed funding: $6M
- Latest round: Seed (Mar 3, 2025)
- Investors on record: 7

## About

Based in Florida, US, and founded in 2020 by Courtney Miller, Patrick Griffin, and Theodore Kamenecka, Myosin Therapeutics Inc., operates as a developer of novel pharmacotherapies targeting members of the myosin family of molecular motors.  In March 2026, Myosin Therapeutics Inc. raised USD 2 million in grant funding.

The company offers various biopharmaceutical solutions that include novel medications targeting cellular motor proteins, and specialized molecular machines that convert energy into mechanical work inside cells. The company's proprietary nMotor system for drug discovery is a full screening platform that enables Myosin to develop a robust pipeline used for the treatment of disorders including cancer, neural regeneration, and other infectious diseases.

The company plans to use the March 2023 funding to advance its treatments for glioblastoma and stimulant use disorder.

## Funding rounds

- Seed, Mar 3, 2025, $3M — Mayo Clinic Ventures, Florida Opportunity Fund, DeepWork Capital, Sontag Foundation, Mint12 Pharma, LLC, Dynagrow Capital
- Seed, Dec 2, 2022, $3M — University of Florida, Florida Opportunity Fund, DeepWork Capital, Mint12 Pharma, LLC

## Investors

- University of Florida — Seed
- Florida Opportunity Fund (https://capitalatlas.ai/funds/florida-opportunity-fund) — Seed
- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Seed
- Mint12 Pharma, LLC — Seed
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Seed
- Sontag Foundation (https://capitalatlas.ai/funds/sontag-foundation) — Seed
- Dynagrow Capital — Seed